Skip to main content
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Main navigation - Mobile
6. Gilead Sciences
Gilead elevates M&A architect Dickinson to CFO
Tuesday, October 15, 2019
Gilead Sciences has found a new chief financial officer in an appointment that has mergers and acquisitions written all over it.
Gilead's exec search won't hurt its deal search: CEO
Wednesday, July 31, 2019
Gilead CEO Daniel O’Day has some holes to fill when it comes to exec hiring. But he insists the C-suite search won’t slow the company’s M&A search.
Should Gilead pick up Celgene's Otezla? Some analysts vote yes
Friday, July 19, 2019
Gilead will need to build out a commercial immunology team as its JAK inhibitor filgotinib nears an FDA filing.
Gilead CEO O'Day continues top-level revamp with two exec exits
Wednesday, July 17, 2019
New Gilead CEO Daniel O’Day has already replaced some key leaders at the company, but he’s not stopping there with the executive overhaul.
Gilead snags Lilly exec Shaw for Kite CEO position
Thursday, July 11, 2019
Back in May, new Gilead CEO Daniel O’Day said he’d be looking for a CEO for Gilead’s Kite unit. And he’s found his pick.
U.S. reps question Gilead's donation of free HIV drug Truvada
Thursday, June 27, 2019
U.S. Rep. Elijah Cummings is leading an effort to determine if Gilead's largesse is tied to its efforts to protect Truvada's patents.
Gilead chief steals BMS' Mercier for top commercial job
Wednesday, May 29, 2019
Bristol-Myers Squibb is losing another key commercial cog, and this time Gilead is the culprit.
Gilead's O'Day takes congressional hot seat to defend Truvada
Friday, May 17, 2019
Gilead's Truvada for PrEP is only getting to about 10% of people who could benefit, according to testimony Thursday.
New Gilead chief plots Kite CEO hire, pipeline M&A
Friday, May 3, 2019
Gilead tapped new CEO Daniel O’Day in part because of his cancer expertise. But he’s not planning to lead the company’s oncology ramp-up alone.